Enhanced HIF1α inhibition was shown upon the combination treatment of palbociclib and TAS-116 in ASPC1 and HPAFII pancreatic cancer cell lines (Supplementary Fig. S8A, B) as well as SKBR3 and MDA-MB-361 breast cancer cells (Supplementary Fig. S8C, D). The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.